SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
159
Participants
Timeline
Start Date
October 31, 2025
Primary Completion Date
November 30, 2027
Study Completion Date
December 31, 2028
Conditions
Type 1 Diabetes
Interventions
DRUG
High Dose SAB-142
High Dose SAB-142
DRUG
Low Dose SAB-142
Low Dose SAB-142
OTHER
Placebo
Placebo
All Listed Sponsors
lead
SAb Biotherapeutics, Inc.
INDUSTRY
NCT07187531 - SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Biotech Hunter | Biotech Hunter